Summary of the Conference Call for Peijia Medical Company Overview - **Company**: Peijia Medical - **Industry**: Medical Devices, specifically focusing on structural heart disease and neurointervention Key Points Financial Performance - **2025 Revenue Growth**: Achieved a 15.8% increase in overall revenue, with core businesses (valve and neurointervention) showing significant cash flow improvements, rising from 0.2 billion to 0.7 billion RMB [2][3] - **Operating Cash Flow**: Core businesses generated positive cash flow of approximately 7 million RMB in 2025, a significant improvement from a negative cash flow of 20 million RMB [4][3] - **Cost Management**: Sales, management, and R&D expenses decreased in absolute terms, leading to a notable reduction in expense ratios, indicating effective operational leverage [3][4] Business Segments Performance - **Valve Business**: - 2025 saw approximately 3,900 valve implants, with a market share increase to 26.4% [2][5] - The TaurusElite valve for aortic regurgitation is expected to contribute 1,500 implants in 2026 [2] - The company aims for a 30% increase in implant volume in 2026, targeting 5,000 implants [3][11] - **Neurointervention Business**: - Revenue grew nearly 20% in 2025, with a market share of nearly 20% for thrombectomy stents, maintaining the leading position among domestic brands [2][8] - The DCY micro-guidewire received FDA approval, opening access to a global market worth 1.5 billion USD [2][9] Market Dynamics - **Impact of Healthcare Pricing Policies**: Recent adjustments in healthcare pricing have had a mild impact, with a significant increase in surgical volume expected in Q1 2026 [2][5] - **Product Portfolio**: The company has a competitive product pipeline, including first and second-generation products for aortic stenosis and the TaurusElite for aortic regurgitation, enhancing market competitiveness [5][6] International Expansion - **Outreach Strategy**: Focus on high-end markets in Europe and the US, with the GeminiOne mitral valve clip already registered in Europe [2][12] - **Funding for R&D**: The company plans to support R&D through external financing, particularly for cutting-edge technology without impacting core business cash flow [4][20] Future Outlook - **2026 Projections**: The company anticipates 2026 to be a year of accelerated growth, aiming for breakeven at the group level and significant revenue increases in both valve and neurointervention segments [11][29] - **Sales Strategy**: Emphasis on product differentiation and maintaining a comprehensive product line to address various market segments, ensuring resilience against price competition [17][18] Regulatory and Clinical Developments - **Clinical Trials**: Ongoing clinical trials for products like Monarch and GeminiOne, with expected advancements in regulatory approvals [20][21] - **Market Positioning**: The company is strategically positioned to leverage its innovative capabilities in the structural heart disease sector, aiming to enhance its reputation internationally [30] Competitive Landscape - **New Entrants**: The company acknowledges the challenges posed by new competitors but remains confident in its established market position and product competitiveness [27] Conclusion - **Long-term Strategy**: Peijia Medical is committed to balancing immediate financial performance with long-term growth potential, focusing on innovation and market expansion to enhance shareholder value [30]